RHOSTATIN Trademark

Trademark Overview

On Thursday, February 6, 2003, a trademark application was filed for RHOSTATIN with the United States Patent and Trademark Office. The USPTO has given the RHOSTATIN trademark a serial number of 78211933. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, December 27, 2013. This trademark is owned by BioAxone Therapeutique Inc.. The RHOSTATIN trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals, namely therapeutic drugs administered in the treatment of cancer
rhostatin

General Information

Serial Number78211933
Word MarkRHOSTATIN
Filing DateThursday, February 6, 2003
Status710 - CANCELLED - SECTION 8
Status DateFriday, December 27, 2013
Registration Number3243483
Registration DateTuesday, May 22, 2007
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 6, 2007

Trademark Statements

Goods and ServicesPharmaceuticals, namely therapeutic drugs administered in the treatment of cancer

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, December 27, 2013
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBioAxone Therapeutique Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressMontreal, Quebec H2X 3P9
CA
Party NameBioAxone Therapeutique Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressMontreal, Quebec H2X 3P9
CA
Party NameBioAxone Therapeutique Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressMontreal, Quebec H2X 3P9
CA

Trademark Events

Event DateEvent Description
Friday, December 27, 2013CANCELLED SEC. 8 (6-YR)
Tuesday, May 22, 2007REGISTERED-PRINCIPAL REGISTER
Thursday, March 8, 2007REVIEW OF CORRESPONDENCE COMPLETE
Tuesday, March 6, 2007PUBLISHED FOR OPPOSITION
Wednesday, February 14, 2007NOTICE OF PUBLICATION
Friday, February 2, 2007PAPER RECEIVED
Thursday, January 18, 2007LAW OFFICE PUBLICATION REVIEW COMPLETED
Tuesday, January 16, 2007APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, January 11, 2007EXAMINER'S AMENDMENT ENTERED
Thursday, January 11, 2007EXAMINERS AMENDMENT MAILED
Thursday, January 11, 2007EXAMINERS AMENDMENT -WRITTEN
Friday, January 5, 2007AMENDMENT FROM APPLICANT ENTERED
Friday, December 1, 2006CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, January 5, 2007ASSIGNED TO LIE
Friday, December 1, 2006PAPER RECEIVED
Wednesday, October 11, 2006INQUIRY AS TO SUSPENSION MAILED
Tuesday, October 10, 2006SUSPENSION INQUIRY WRITTEN
Thursday, September 14, 2006LIE CHECKED SUSP - TO ATTY FOR ACTION
Thursday, March 16, 2006APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, February 7, 2006PAPER RECEIVED
Thursday, February 16, 2006REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Wednesday, June 15, 2005LETTER OF SUSPENSION MAILED
Tuesday, June 14, 2005SUSPENSION LETTER WRITTEN
Friday, June 10, 2005AMENDMENT FROM APPLICANT ENTERED
Thursday, May 5, 2005CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, May 5, 2005PAPER RECEIVED
Tuesday, January 4, 2005INQUIRY AS TO SUSPENSION MAILED
Monday, January 3, 2005SUSPENSION INQUIRY WRITTEN
Wednesday, December 8, 2004LIE CHECKED SUSP - TO ATTY FOR ACTION
Monday, May 24, 2004LETTER OF SUSPENSION MAILED
Monday, May 3, 2004CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, May 3, 2004PAPER RECEIVED
Tuesday, March 23, 2004INQUIRY AS TO SUSPENSION MAILED
Tuesday, August 5, 2003LETTER OF SUSPENSION MAILED
Thursday, July 31, 2003ASSIGNED TO EXAMINER

Related Keywords

rhostatin treatment cancer administered drugs namely therapeutic pharmaceuticals